Skip to main content
SpringerLink
Log in

Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer

  • Case Report
  • Published:
Journal of Infection and Chemotherapy

Abstract

S-1 is an oral 5-fluorouracil (5-FU) anticancer agent and has shown promising effects in the treatment of a wide range of carcinomas, including head and neck cancer. In addition to being used as adjuvant chemotherapy, S-1 is a promising agent for palliative treatment. Its ease of administration makes it an ideal drug to treat patients in the outpatient setting while maintaining adequate quality of life. However, the clinical role of S-1 in patients with recurrent/metastatic head and neck cancer is still uncertain. We retrospectively reviewed 16 patients with recurrent/metastatic head and neck cancer who received S-1 monotherapy. Thirteen patients with squamous cell carcinoma (SCC) and 3 patients with non-SCC who had recurrent/metastatic disease received S-1 monotherapy as outpatients. One patient with nasopharyngeal undifferentiated carcinoma and 1 patient with maxillary adenosquamous carcinoma showed complete response (CR), while all SCC patients showed stable disease (SD) or progressive disease (PD). Median time to progression (TTP) was 12 weeks. Five patients showed grade 3 and 4 adverse reactions, all hematological. Except for one episode of grade 4 leucopenia which required hospitalization and granulocyte colony-stimulating factor (GCSF) treatment, all adverse events resolved with dose reduction or dose omission. S-1 was safely administered in outpatients and showed some efficacy in the treatment of recurrent/metastatic head and neck cancer in patients who had received previous chemotherapy. S-1 could be used as palliative treatment in patients with recurrent/metastatic head and neck cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153–156.

    Article  CAS  PubMed  Google Scholar 

  2. Seiwert TY, Cohen EE: State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 2005;92:1341–1348.

    Article  CAS  PubMed  Google Scholar 

  3. Alvi A, Johnson JT. Development of distant metastasis after treatment of advanced-stage head and neck cancer. Head Neck 1997;19:500–505.

    Article  CAS  PubMed  Google Scholar 

  4. Cooper JS, Pajak TF, Forastiere A, Jacobs J, Fu KK, Ang KK, et al. Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy? Head Neck 1998;20:588–594.

    Article  CAS  PubMed  Google Scholar 

  5. Kish JA, Weaver A, Jacobs J, Cummings G, Al-Sarraf M. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 1984;53:1819–1824.

    Article  CAS  PubMed  Google Scholar 

  6. Mercier RJ, Neal GD, Mattox DE, Gates GA, Pomeroy TC, Von Hoff DD. Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 1987;60:2609–2612.

    Article  CAS  PubMed  Google Scholar 

  7. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602–2606.

    CAS  PubMed  Google Scholar 

  8. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548–557.

    Article  CAS  PubMed  Google Scholar 

  9. Schoffski P. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 2004;15:85–106.

    Article  PubMed  Google Scholar 

  10. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi, T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34: 1715–1720.

    Article  CAS  PubMed  Google Scholar 

  11. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000;58:191–197.

    Article  CAS  PubMed  Google Scholar 

  12. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, et al. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 2000;83:141–145.

    Article  CAS  PubMed  Google Scholar 

  13. Nishimura G, Yanoma S, Mizuno H, Satake K, Taguchi T, Ikeda Y, et al. Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells. Cancer Lett 2000;159:1–7.

    Article  CAS  PubMed  Google Scholar 

  14. Shien T, Shimizu C, Akashi-Tanaka S, Yonemori K, Kohno T, Hojo T, et al. Clinical efficacy of S-1 in pretreated metastatic breast cancer patients. Jpn J Clin Oncol 2008;38:172–175.

    Article  PubMed  Google Scholar 

  15. Tetzlaff ED, Faust J, Ajani JA. Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatin. Gastric Cancer 2006;9:140–143.

    Article  PubMed  Google Scholar 

  16. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 2001;28:1381–1390.

    CAS  PubMed  Google Scholar 

  17. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988;6:1653–1664.

    CAS  PubMed  Google Scholar 

  18. Caballero GA, Ausman RK, Quebbeman EJ. Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas. Cancer Treat Rep 1985;69:13–15.

    CAS  PubMed  Google Scholar 

  19. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425–432.

    CAS  PubMed  Google Scholar 

  20. Quebbeman E, Ausman R, Hansen R, Becker T, Caballero G, Ritch P, et al. Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil. J Surg Oncol 1985;30:60–65.

    Article  CAS  PubMed  Google Scholar 

  21. Tsukuda M, Ogasawara H, Kaneko S, Komiyama S, Horiuchi M, Inuyama Y, et al. A prospective randomized trial of adjuvant chemotherapy with UFT for head and neck carcinoma. Head and Neck UFT Study Group. Gan To Kagaku Ryoho 1994;21: 1169–1177.

    CAS  PubMed  Google Scholar 

  22. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713–1721.

    Article  CAS  PubMed  Google Scholar 

  23. Noguchi S, Koyama H, Uchino J, Abe R, Miura S, Sugimachi K, et al. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials. J Clin Oncol 2005;23:2172–2184.

    Article  CAS  PubMed  Google Scholar 

  24. Moynihan T, Hansen R, Anderson T, Quebbeman E, Beatty P, Ausman R, et al. Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 1988;11:461–464.

    Article  CAS  PubMed  Google Scholar 

  25. Morita S, Nakata B, Tsuji A, Mitachi Y, Shirasaka T, Saji S, et al. A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method. Jpn J Clin Oncol 2007;37:924–929.

    Article  PubMed  Google Scholar 

  26. Morise Z, Sugioka A, Fujita J, Hoshimoto S, Kato T, Ikeda M. S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas. Hepatogastroenterology 2007;54: 2315–2318.

    CAS  PubMed  Google Scholar 

  27. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215–221.

    Article  CAS  PubMed  Google Scholar 

  28. Kodaira T, Fuwa N, Tachibana H, Hidano S. Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer. Anticancer Res 2006;26:2265–2268.

    CAS  PubMed  Google Scholar 

  29. Watanabe A, Taniguchi M, Yamashita T, Ueda M, Abe T, Kusumi T, et al. Phase I/II study of S-1 combined with carboplatin in recurrent and/or metastatic head and neck cancer as outpatient chemotherapy. Head Neck 2006;28:620–625.

    Article  PubMed  Google Scholar 

  30. Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C, et al. Nasopharyngeal carcinomas: an update. Eur J Cancer 2003;39:2121–2135.

    Article  PubMed  Google Scholar 

  31. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003;21:631–637.

    Article  PubMed  Google Scholar 

  32. Alos L, Castillo M, Nadal A, Caballero M, Mallofre C, Palacin A, et al. Adenosquamous carcinoma of the head and neck: criteria for diagnosis in a study of 12 cases. Histopathology 2004;44: 570–579.

    Article  CAS  PubMed  Google Scholar 

  33. Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, et al. Phase I study of S-1. S-1 Study Group. Gan To Kagaku Ryoho 1997;24:2253–2264.

    CAS  PubMed  Google Scholar 

  34. Tsukuda M, Kida A, Fujii M, Kono N, Yoshihara T, Hasegawa Y, et al. Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer 2005;93:884–889.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Sensory Medicine, Departments of Otolaryngology and Head and Neck Surgery, Akita University School of Medicine, Akita, Akita, 010-0851, Japan

    Shinsuke Suzuki & Kazuo Ishikawa

Authors
  1. Shinsuke Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuo Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shinsuke Suzuki.

About this article

Cite this article

Suzuki, S., Ishikawa, K. Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer. J Infect Chemother 15, 335–339 (2009). https://doi.org/10.1007/s10156-009-0712-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10156-009-0712-x

Key words

Search

Navigation